nach oben

Erschienen in:

05.08.2020 | Topic Review

Nanoparticles as immunomodulators and translational agents in brain tumors

verfasst von: Adam J. Grippin, Kyle A. Dyson, Sadeem Qdaisat, James McGuiness, Brandon Wummer, Duane A. Mitchell, Hector R. Mendez-Gomez, Elias J. Sayour

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Brain tumors remain especially challenging to treat due to the presence of the blood–brain barrier. The unique biophysical properties of nanomaterials enable access to the tumor environment with minimally invasive injection methods such as intranasal and systemic delivery.

Methods

In this review, we will discuss approaches taken in NP delivery to brain tumors in preclinical neuro-oncology studies and ongoing clinical studies.

Results

Despite recent development of many promising nanoparticle systems to modulate immunologic function in the preclinical realm, clinical work with nanoparticles in malignant brain tumors has largely focused on imaging, chemotherapy, thermotherapy and radiation.

Conclusion

Review of early preclinical studies and clinical trials provides foundational safety, feasibility and toxicology data that can usher a new wave of nanotherapeutics in application of immunotherapy and translational oncology for patients with brain tumors.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330CrossRefPubMed

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain Radiation Oncology T G, National Cancer Institute of Canada Clinical Trials G (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7CrossRefPubMed

Schreck KC, Grossman SA (2018) Role of temozolomide in the treatment of cancers involving the central nervous system. Oncology (Williston Park) 32:555–560

Wolff JE, Finlay JL (2004) High-dose chemotherapy in childhood brain tumors. Onkologie 27:239–245. https://doi.org/10.1159/000077973CrossRefPubMed

Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol 13:317–323. https://doi.org/10.1093/neuonc/noq191CrossRefPubMedPubMedCentral

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC, Investigators K- (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005CrossRefPubMed

Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550–4557. https://doi.org/10.1158/1078-0432.CCR-11-0116CrossRefPubMedPubMedCentral

Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733. https://doi.org/10.1056/NEJMoa1103849CrossRefPubMedPubMedCentral

Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2011) The brain tumor microenvironment. Glia 59:1169–1180. https://doi.org/10.1002/glia.21136CrossRefPubMed

10.

Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605–612. https://doi.org/10.1158/0008-5472.CAN-05-4005CrossRefPubMed

11.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O’Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH, investigators AIt (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:1373–1385. https://doi.org/10.1016/S1470-2045(17)30517-XCrossRefPubMed

12.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442CrossRefPubMed

13.

Zhang F, Stephan SB, Ene CI, Smith TT, Holland EC, Stephan MT (2018) Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T-cell therapy in solid malignancies. Cancer Res 78:3718–3730. https://doi.org/10.1158/0008-5472.CAN-18-0306CrossRefPubMedPubMedCentral

14.

Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83:761–769. https://doi.org/10.1038/sj.clpt.6100400CrossRefPubMed

15.

Zhang Y, Li N, Suh H, Irvine DJ (2018) Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat Commun 9:6. https://doi.org/10.1038/s41467-017-02251-3CrossRefPubMedPubMedCentral

16.

Li L, Jiang W, Luo K, Song H, Lan F, Wu Y, Gu Z (2013) Superparamagnetic iron oxide nanoparticles as MRI contrast agents for non-invasive stem cell labeling and tracking. Theranostics 3:595–615. https://doi.org/10.7150/thno.5366CrossRefPubMedPubMedCentral

17.

Toraya-Brown S, Sheen MR, Zhang P, Chen L, Baird JR, Demidenko E, Turk MJ, Hoopes PJ, Conejo-Garcia JR, Fiering S (2014) Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. Nanomedicine 10:1273–1285. https://doi.org/10.1016/j.nano.2014.01.011CrossRefPubMed

18.

Silva GA (2008) Nanotechnology approaches to crossing the blood–brain barrier and drug delivery to the CNS. BMC Neurosci 9(Suppl 3):S4. https://doi.org/10.1186/1471-2202-9-S3-S4CrossRefPubMedPubMedCentral

19.

Saraiva C, Praca C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Cont Rel 235:34–47. https://doi.org/10.1016/j.jconrel.2016.05.044CrossRef

20.

Song Q, Song H, Xu J, Huang J, Hu M, Gu X, Chen J, Zheng G, Chen H, Gao X (2016) Biomimetic ApoE-reconstituted high density lipoprotein nanocarrier for blood–brain barrier penetration and amyloid beta-targeting drug delivery. Mol Pharm 13:3976–3987. https://doi.org/10.1021/acs.molpharmaceut.6b00781CrossRefPubMed

21.

Sayour EJ, De Leon G, Pham C, Grippin A, Kemeny H, Chua J, Huang J, Sampson JH, Sanchez-Perez L, Flores C, Mitchell DA (2017) Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. Oncoimmunology 6:e1256527. https://doi.org/10.1080/2162402X.2016.1256527CrossRefPubMed

22.

Sayour EJ, Grippin A, De Leon G, Stover B, Rahman M, Karachi A, Wummer B, Moore G, Castillo-Caro P, Fredenburg K, Sarkisian MR, Huang J, Deleyrolle LP, Sahay B, Carrera-Justiz S, Mendez-Gomez HR, Mitchell DA (2018) Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy. Nano Lett 18:6195–6206. https://doi.org/10.1021/acs.nanolett.8b02179CrossRefPubMedPubMedCentral

23.

Adiseshaiah PP, Hall JB, McNeil SE (2010) Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:99–112. https://doi.org/10.1002/wnan.66CrossRefPubMed

24.

Xue HY, Liu S, Wong HL (2014) Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond) 9:295–312. https://doi.org/10.2217/nnm.13.204CrossRef

25.

Kedmi R, Ben-Arie N, Peer D (2010) The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31:6867–6875. https://doi.org/10.1016/j.biomaterials.2010.05.027CrossRefPubMed

26.

Grippin AJ, Sayour EJ, Mitchell DA (2017) Translational nanoparticle engineering for cancer vaccines. Oncoimmunology 6:e1290036. https://doi.org/10.1080/2162402X.2017.1290036CrossRefPubMedPubMedCentral

27.

Householder KT, DiPerna DM, Chung EP, Wohlleb GM, Dhruv HD, Berens ME, Sirianni RW (2015) Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma. Int J Pharm 479:374–380. https://doi.org/10.1016/j.ijpharm.2015.01.002CrossRefPubMed

28.

Jia Y, Wang X, Hu D, Wang P, Liu Q, Zhang X, Jiang J, Liu X, Sheng Z, Liu B, Zheng H (2019) Phototheranostics: active targeting of orthotopic glioma using biomimetic proteolipid nanoparticles. ACS Nano 13:386–398. https://doi.org/10.1021/acsnano.8b06556CrossRefPubMed

29.

Shevtsov M, Stangl S, Nikolaev B, Yakovleva L, Marchenko Y, Tagaeva R, Sievert W, Pitkin E, Mazur A, Tolstoy P, Galibin O, Ryzhov V, Steiger K, Smirnov O, Khachatryan W, Chester K, Multhoff G (2019) Granzyme B functionalized nanoparticles targeting membrane Hsp70-positive tumors for multimodal cancer theranostics. Small 15:e1900205. https://doi.org/10.1002/smll.201900205CrossRefPubMed

30.

Sun Z, Zhang Y, Cao D, Wang X, Yan X, Li H, Huang L, Qu X, Kong C, Qin H, Wang M, Xu W, Liang L (2018) PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer. Drug Deliv 25:1746–1755. https://doi.org/10.1080/10717544.2018.1509907CrossRefPubMedPubMedCentral

31.

Erel-Akbaba G, Carvalho LA, Tian T, Zinter M, Akbaba H, Obeid PJ, Chiocca EA, Weissleder R, Kantarci AG, Tannous BA (2019) Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy. ACS Nano 13:4028–4040. https://doi.org/10.1021/acsnano.8b08177CrossRefPubMedPubMedCentral

32.

Shibata S, Shinozaki N, Suganami A, Ikegami S, Kinoshita Y, Hasegawa R, Kentaro H, Okamoto Y, Aoki I, Tamura Y, Iwadate Y (2019) Photo-immune therapy with liposomally formulated phospholipid-conjugated indocyanine green induces specific antitumor responses with heat shock protein-70 expression in a glioblastoma model. Oncotarget 10:175–183. https://doi.org/10.18632/oncotarget.26544CrossRefPubMedPubMedCentral

33.

Tsai YC, Vijayaraghavan P, Chiang WH, Chen HH, Liu TI, Shen MY, Omoto A, Kamimura M, Soga K, Chiu HC (2018) Targeted delivery of functionalized upconversion nanoparticles for externally triggered photothermal/photodynamic therapies of brain glioblastoma. Theranostics 8:1435–1448. https://doi.org/10.7150/thno.22482CrossRefPubMedPubMedCentral

34.

Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, Holland EC, Stephan MT (2019) Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun 10:3974. https://doi.org/10.1038/s41467-019-11911-5CrossRefPubMedPubMedCentral

35.

Zhao P, Wang Y, Kang X, Wu A, Yin W, Tang Y, Wang J, Zhang M, Duan Y, Huang Y (2018) Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy. Chem Sci 9:2674–2689. https://doi.org/10.1039/c7sc04853jCrossRefPubMedPubMedCentral

36.

Saxena T, Lyon JG, Pai SB, Pare D, Amero J, Karumbaiah L, Carroll SL, Gaupp E, Bellamkonda RV (2019) Engineering controlled peritumoral inflammation to constrain brain tumor growth. Adv Healthc Mater 8:e1801076. https://doi.org/10.1002/adhm.201801076CrossRefPubMed

37.

Li TF, Li K, Wang C, Liu X, Wen Y, Xu YH, Zhang Q, Zhao QY, Shao M, Li YZ, Han M, Komatsu N, Zhao L, Chen X (2017) Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment. J Control Release 268:128–146. https://doi.org/10.1016/j.jconrel.2017.10.024CrossRefPubMed

38.

Wu C, Muroski ME, Miska J, Lee-Chang C, Shen Y, Rashidi A, Zhang P, Xiao T, Han Y, Lopez-Rosas A, Cheng Y, Lesniak MS (2019) Repolarization of myeloid derived suppressor cells via magnetic nanoparticles to promote radiotherapy for glioma treatment. Nanomedicine 16:126–137. https://doi.org/10.1016/j.nano.2018.11.015CrossRefPubMed

39.

Schneider T, Becker A, Ringe K, Reinhold A, Firsching R, Sabel BA (2008) Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 195:21–27. https://doi.org/10.1016/j.jneuroim.2007.12.005CrossRefPubMed

40.

Ruan S, Xie R, Qin L, Yu M, Xiao W, Hu C, Yu W, Qian Z, Ouyang L, He Q, Gao H (2019) Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment. Nano Lett. https://doi.org/10.1021/acs.nanolett.9b03968CrossRefPubMed

41.

Qiao C, Yang J, Shen Q, Liu R, Li Y, Shi Y, Chen J, Shen Y, Xiao Z, Weng J, Zhang X (2018) Traceable nanoparticles with dual targeting and ROS response for RNAi-based immunochemotherapy of intracranial glioblastoma treatment. Adv Mater 30:e1705054. https://doi.org/10.1002/adma.201705054CrossRefPubMed

42.

Yaghi NK, Wei J, Hashimoto Y, Kong LY, Gabrusiewicz K, Nduom EK, Ling X, Huang N, Zhou S, Kerrigan BC, Levine JM, Fajt VR, Levine G, Porter BF, Marcusson EG, Tachikawa K, Chivukula P, Webb DC, Payne JE, Heimberger AB (2017) Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro Oncol 19:372–382. https://doi.org/10.1093/neuonc/now198CrossRefPubMed

43.

Shevtsov MA, Nikolaev BP, Yakovleva LY, Parr MA, Marchenko YY, Eliseev I, Yudenko A, Dobrodumov AV, Zlobina O, Zhakhov A, Ischenko AM, Pitkin E, Multhoff G (2015) 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma. J Control Release 220:329–340. https://doi.org/10.1016/j.jconrel.2015.10.051CrossRefPubMed

44.

Yuan B, Shen H, Su T, Lin L, Chen T, Yang Z (2015) A novel nanoparticle containing neuritin peptide with grp170 induces a CTL response to inhibit tumor growth. J Neurooncol 125:23–32. https://doi.org/10.1007/s11060-015-1884-0CrossRefPubMed

45.

Alphandery E, Idbaih A, Adam C, Delattre JY, Schmitt C, Guyot F, Chebbi I (2017) Chains of magnetosomes with controlled endotoxin release and partial tumor occupation induce full destruction of intracranial U87-Luc glioma in mice under the application of an alternating magnetic field. J Control Release 262:259–272. https://doi.org/10.1016/j.jconrel.2017.07.020CrossRefPubMed

46.

Sehedic D, Chourpa I, Tetaud C, Griveau A, Loussouarn C, Avril S, Legendre C, Lepareur N, Wion D, Hindre F, Davodeau F, Garcion E (2017) Locoregional confinement and major clinical benefit of (188)re-loaded CXCR4-targeted nanocarriers in an orthotopic human to mouse model of glioblastoma. Theranostics 7:4517–4536. https://doi.org/10.7150/thno.19403CrossRefPubMedPubMedCentral

47.

Kadiyala P, Li D, Nunez FM, Altshuler D, Doherty R, Kuai R, Yu M, Kamran N, Edwards M, Moon JJ, Lowenstein PR, Castro MG, Schwendeman A (2019) High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano 13:1365–1384. https://doi.org/10.1021/acsnano.8b06842CrossRefPubMedPubMedCentral

48.

Kerstetter-Fogle A, Shukla S, Wang C, Beiss V, Harris PLR, Sloan AE, Steinmetz NF (2019) Plant virus-like particle in situ vaccine for intracranial glioma immunotherapy. Cancers (Basel). https://doi.org/10.3390/cancers11040515CrossRefPubMedCentral

49.

Schneider CS, Perez JG, Cheng E, Zhang C, Mastorakos P, Hanes J, Winkles JA, Woodworth GF, Kim AJ (2015) Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells. Biomaterials 42:42–51. https://doi.org/10.1016/j.biomaterials.2014.11.054CrossRefPubMedPubMedCentral

50.

Van Woensel M, Mathivet T, Wauthoz N, Rosiere R, Garg AD, Agostinis P, Mathieu V, Kiss R, Lefranc F, Boon L, Belmans J, Van Gool SW, Gerhardt H, Amighi K, De Vleeschouwer S (2017) Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Sci Rep 7:1217. https://doi.org/10.1038/s41598-017-01279-1CrossRefPubMedPubMedCentral

51.

Van Woensel M, Wauthoz N, Rosiere R, Mathieu V, Kiss R, Lefranc F, Steelant B, Dilissen E, Van Gool SW, Mathivet T, Gerhardt H, Amighi K, De Vleeschouwer S (2016) Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J Control Release 227:71–81. https://doi.org/10.1016/j.jconrel.2016.02.032CrossRefPubMed

52.

Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivisakk P, Tucky B, Kidd G, Kingsbury GA, Chang A, Fox RJ, Mack M, Sniderman MB, Ravid R, Staugaitis SM, Stins MF, Ransohoff RM (2006) Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129:212–223. https://doi.org/10.1093/brain/awh655CrossRefPubMed

53.

Takeshita Y, Ransohoff RM (2012) Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev 248:228–239. https://doi.org/10.1111/j.1600-065X.2012.01127.xCrossRefPubMedPubMedCentral

54.

Ransohoff RM, Kivisakk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3:569–581. https://doi.org/10.1038/nri1130CrossRefPubMed

55.

Sattiraju A, Xiong X, Pandya DN, Wadas TJ, Xuan A, Sun Y, Jung Y, Solingapuram Sai KK, Dorsey JF, Li KC, Mintz A (2017) Alpha particle enhanced blood brain/tumor barrier permeabilization in glioblastomas using integrin alpha-v beta-3 targeted liposomes. Mol Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-16-0907CrossRefPubMedPubMedCentral

56.

Baumann BC, Kao GD, Mahmud A, Harada T, Swift J, Chapman C, Xu X, Discher DE, Dorsey JF (2013) Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy. Oncotarget 4:64–79. https://doi.org/10.18632/oncotarget.777CrossRefPubMedPubMedCentral

57.

Zhou K, Bostrom M, Ek CJ, Li T, Xie C, Xu Y, Sun Y, Blomgren K, Zhu C (2017) Radiation induces progenitor cell death, microglia activation, and blood-brain barrier damage in the juvenile rat cerebellum. Sci Rep 7:46181. https://doi.org/10.1038/srep46181CrossRefPubMedPubMedCentral

58.

Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–782. https://doi.org/10.1038/nrd2614CrossRefPubMed

59.

Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91:2076–2080. https://doi.org/10.1073/pnas.91.6.2076CrossRefPubMedPubMedCentral

60.

Young JS, Bernal G, Polster SP, Nunez L, Larsen GF, Mansour N, Podell M, Yamini B (2018) Convection-enhanced delivery of polymeric nanoparticles encapsulating chemotherapy in canines with spontaneous supratentorial tumors. World Neurosurg 117:e698–e704. https://doi.org/10.1016/j.wneu.2018.06.114CrossRefPubMedPubMedCentral

61.

Plotkin M, Gneveckow U, Meier-Hauff K, Amthauer H, Feussner A, Denecke T, Gutberlet M, Jordan A, Felix R, Wust P (2006) 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Int J Hyperthermia 22:319–325. https://doi.org/10.1080/02656730600734128CrossRefPubMed

62.

Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, Feussner A, von Deimling A, Waldoefner N, Felix R, Jordan A (2007) Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 81:53–60. https://doi.org/10.1007/s11060-006-9195-0CrossRefPubMed

63.

Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A (2011) Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 103:317–324. https://doi.org/10.1007/s11060-010-0389-0CrossRefPubMed

64.

Grauer O, Jaber M, Hess K, Weckesser M, Schwindt W, Maring S, Wolfer J, Stummer W (2019) Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients. J Neurooncol 141:83–94. https://doi.org/10.1007/s11060-018-03005-xCrossRefPubMed

65.

Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM (2009) A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res 15:5569–5575. https://doi.org/10.1158/1078-0432.CCR-09-0522CrossRefPubMedPubMedCentral

66.

Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kummel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G, German Breast G (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17:345–356. https://doi.org/10.1016/S1470-2045(15)00542-2CrossRefPubMed

67.

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, Investigators IMT (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108–2121. https://doi.org/10.1056/NEJMoa1809615CrossRefPubMed

68.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324. https://doi.org/10.1158/1078-0432.CCR-05-1634CrossRefPubMed

69.

Enochs WS, Harsh G, Hochberg F, Weissleder R (1999) Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 9:228–232CrossRefPubMed

70.

Nguyen KL, Yoshida T, Kathuria-Prakash N, Zaki IH, Varallyay CG, Semple SI, Saouaf R, Rigsby CK, Stoumpos S, Whitehead KK, Griffin LM, Saloner D, Hope MD, Prince MR, Fogel MA, Schiebler ML, Roditi GH, Radjenovic A, Newby DE, Neuwelt EA, Bashir MR, Hu P, Finn JP (2019) Multicenter safety and practice for off-label diagnostic use of ferumoxytol in MRI. Radiology. https://doi.org/10.1148/radiol.2019190477CrossRefPubMed

71.

Corot C, Petry KG, Trivedi R, Saleh A, Jonkmanns C, Le Bas JF, Blezer E, Rausch M, Brochet B, Foster-Gareau P, Baleriaux D, Gaillard S, Dousset V (2004) Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol 39:619–625. https://doi.org/10.1097/01.rli.0000135980.08491.33CrossRefPubMed

72.

Manninger SP, Muldoon LL, Nesbit G, Murillo T, Jacobs PM, Neuwelt EA (2005) An exploratory study of ferumoxtran-10 nanoparticles as a blood–brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. AJNR Am J Neuroradiol 26:2290–2300PubMedPubMedCentral

73.

Saleh A, Schroeter M, Ringelstein A, Hartung HP, Siebler M, Modder U, Jander S (2007) Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke. Stroke 38:2733–2737. https://doi.org/10.1161/STROKEAHA.107.481788CrossRefPubMed

74.

McConnell HL, Schwartz DL, Richardson BE, Woltjer RL, Muldoon LL, Neuwelt EA (2016) Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific. Nanomedicine 12:1535–1542. https://doi.org/10.1016/j.nano.2016.03.009CrossRefPubMed

75.

Hamilton BE, Woltjer RL, Prola-Netto J, Nesbit GM, Gahramanov S, Pham T, Wagner J, Neuwelt EA (2016) Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations. J Neurooncol 129:301–309. https://doi.org/10.1007/s11060-016-2175-0CrossRefPubMed

76.

Barajas RF, Hamilton BE, Schwartz D, McConnell HL, Pettersson DR, Horvath A, Szidonya L, Varallyay CG, Firkins J, Jaboin JJ, Kubicky CD, Raslan AM, Dogan A, Cetas JS, Ciporen J, Han SJ, Ambady P, Muldoon LL, Woltjer R, Rooney WD, Neuwelt EA (2019) Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression. Neuro Oncol 21:517–526. https://doi.org/10.1093/neuonc/noy160CrossRefPubMed

77.

Lux F, Tran VL, Thomas E, Dufort S, Rossetti F, Martini M, Truillet C, Doussineau T, Bort G, Denat F, Boschetti F, Angelovski G, Detappe A, Cremillieux Y, Mignet N, Doan BT, Larrat B, Meriaux S, Barbier E, Roux S, Fries P, Muller A, Abadjian MC, Anderson C, Canet-Soulas E, Bouziotis P, Barberi-Heyob M, Frochot C, Verry C, Balosso J, Evans M, Sidi-Boumedine J, Janier M, Butterworth K, McMahon S, Prise K, Aloy MT, Ardail D, Rodriguez-Lafrasse C, Porcel E, Lacombe S, Berbeco R, Allouch A, Perfettini JL, Chargari C, Deutsch E, Le Duc G, Tillement O (2018) AGuIX((R)) from bench to bedside-transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br J Radiol. https://doi.org/10.1259/bjr.20180365CrossRefPubMedPubMedCentral

78.

Verry C, Sancey L, Dufort S, Le Duc G, Mendoza C, Lux F, Grand S, Arnaud J, Quesada JL, Villa J, Tillement O, Balosso J (2019) Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol. BMJ Open 9:e023591. https://doi.org/10.1136/bmjopen-2018-023591CrossRefPubMedPubMedCentral

79.

Kotb S, Piraquive J, Lamberton F, Lux F, Verset M, Di Cataldo V, Contamin H, Tillement O, Canet-Soulas E, Sancey L (2016) Safety evaluation and imaging properties of gadolinium-based nanoparticles in nonhuman primates. Sci Rep 6:35053. https://doi.org/10.1038/srep35053CrossRefPubMedPubMedCentral

80.

Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor JR (2006) Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol Cancer Ther 5:3162–3169. https://doi.org/10.1158/1535-7163.MCT-06-0480CrossRefPubMed

81.

Madhankumar AB, Slagle-Webb B, Wang X, Yang QX, Antonetti DA, Miller PA, Sheehan JM, Connor JR (2009) Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol Cancer Ther 8:648–654. https://doi.org/10.1158/1535-7163.MCT-08-0853CrossRefPubMed

82.

Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, Wu X, Mao H (2010) EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 70:6303–6312. https://doi.org/10.1158/0008-5472.CAN-10-1022CrossRefPubMedPubMedCentral

Titel: Nanoparticles as immunomodulators and translational agents in brain tumors
verfasst von: Adam J. Grippin
Kyle A. Dyson
Sadeem Qdaisat
James McGuiness
Brandon Wummer
Duane A. Mitchell
Hector R. Mendez-Gomez
Elias J. Sayour
Publikationsdatum: 05.08.2020
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2021
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03559-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Immune suppression in gliomas

Blood–brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors

Journal of Neuro Oncology: immunotherapy for brain tumors

Publisher's Note

Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases